列纳利多米德衍生物和向蛋白解的嵌合体用于控制新基质降解
Satoshi Yamanaka1,2, Hirotake Furihata1,3, Yuta Yanagihara4
1Division of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, 790-8577, Japan.
修改后的莱纳利多米德选择性降解癌症驱动蛋白质,增强向蛋白质降解. 这一突破为多发性骨髓瘤和5q骨髓质疏松综合征提供了更强大的抗癌效应.
科学领域:
- 化学生物学 化学生物学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 列纳利多米德是一种免疫调节药物 (IMiD),是治疗多发性骨髓瘤 (MM) 和5q骨髓质疏松综合征 (5q MDS) 等血液癌症的基石疗法.
- IMiDs的功能是分子合剂,劫持CRL4CRBN以降解特定的新基质,这是它们治疗作用的核心过程.
- 目前的IMiD和基于IMiD的蛋白质溶解向金马 (PROTAC) 缺乏新基质选择性,降解了参与胚胎发育和疾病进展的蛋白质.
研究的目的:
- 研究莱纳利多米德6位修饰在控制针对蛋白质降解 (TPD) 的新基质选择性的作用.
- 在血液癌症模型中评估新型6位修改的列纳利多米德衍生物及其相应的PROTACs的抗增殖作用.
主要方法:
- 合成和6位置修饰的莱纳利多米德衍生物的表征.
- 使用生化分析评估新基质降解概况.
- 评估MM和5q MDS细胞系中的抗增殖活性.
- 开发和测试针对BET蛋白的基于IMID的PROTACs.
主要成果:
- 6-罗莱纳利多米德证明了对IKZF1,IKZF3和CK1α的选择性降解,这是抗血液癌症活性的关键标.
- 与lenalidomide相比,修改后的lenalidomide衍生物在MM和5q MDS细胞系上表现出优异的抗增殖作用.
- 包含这些衍生物的PROTAC选择性降解BET蛋白,具有一致的新基质选择性和强大的抗增殖活性.
结论:
- 莱纳利多米德6位的修改对于实现选择性新基质降解至关重要.
- 6位修饰的莱纳利多米德衍生物是开发更有选择性和更有效的TPD药物的有希望的策略.
- 这些发现为下一代基于IMiD的疗法铺平了道路,在血液性恶性瘤中提高了疗效,减少了目标外影响.
更多相关视频
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Prodrugs
Prodrugs help overcome...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
